Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalation intraoperative photodynamic therapy with GLIOLAN in glioblastoma
2019-004796-40Phase 2Completed
- Sponsor
- CHU de Lille
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 5-aminolevulinic acid in glioblastoma (GBM), sponsored by CHU de Lille. Primary endpoint: Maximum Tolerated Light Dose (MTLD). Started Jan 2021; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2019-004796-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004796-40.